$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000145983919000035 Filed on August 07, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$16.18M	$16.32M	$13.66M
YoY Change	20.93%	19.42%	22.98%
Cost Of Revenue	$1.630M	$1.588M	$1.182M
YoY Change	33.5%	34.35%	4.6%
Gross Profit	$14.55M	$14.73M	$12.48M
YoY Change	19.67%	18.01%	25.19%
Gross Profit Margin	89.93%	90.27%	91.35%
Selling, General & Admin	$23.26M	$20.92M	$12.88M
YoY Change	68.17%	62.4%	-6.24%
% of Gross Profit	159.83%	142.04%	103.21%
Research & Development	$1.874M	$1.946M	$1.296M
YoY Change	36.49%	50.15%	-4.0%
% of Gross Profit	12.88%	13.21%	10.38%
Depreciation & Amortization	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	-31.03%
% of Gross Profit	1.37%	1.36%	1.6%
Operating Expenses	$25.13M	$22.87M	$14.18M
YoY Change	65.31%	61.29%	-6.04%
Operating Profit	-$10.58M	-$8.138M	-$1.697M
YoY Change	247.6%	379.55%	-66.86%
Interest Expense	$1.243M	$1.233M	$1.269M
YoY Change	-3.04%	-2.84%	-235.0%
% of Operating Profit
Other Income/Expense, Net	-$94.00K	$22.00K	-$249.0K
YoY Change	-82.43%	-108.84%	-231.05%
Pretax Income	-$11.31M	-$8.650M	-$3.150M
YoY Change	136.12%	174.6%	-46.25%
Income Tax
% Of Pretax Income
Net Earnings	-$11.31M	-$8.654M	-$3.147M
YoY Change	135.93%	174.99%	-46.3%
Net Earnings / Revenue	-69.87%	-53.04%	-23.03%
Basic Earnings Per Share
Diluted Earnings Per Share	-$456.0K	-$351.9K	-$872.6K
COMMON SHARES
Basic Shares Outstanding	24.80M shares	24.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$96.22M	$103.3M
YoY Change	587.31%
Cash & Equivalents	$12.61M	$11.50M	$16.23M
Short-Term Investments	$83.61M	$91.78M
Other Short-Term Assets	$1.600M	$1.900M
YoY Change	128.57%
Inventory	$4.953M	$4.436M
Prepaid Expenses
Receivables	$9.918M	$9.404M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$112.7M	$119.0M
YoY Change	353.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.025M	$2.532M
YoY Change	47.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.300M	$5.300M
YoY Change
Other Assets	$305.0K	$310.0K
YoY Change	-79.48%
Total Long-Term Assets	$8.603M	$8.104M
YoY Change	143.44%
TOTAL ASSETS
Total Short-Term Assets	$112.7M	$119.0M
Total Long-Term Assets	$8.603M	$8.104M
Total Assets	$121.3M	$127.1M
YoY Change	327.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.623M	$2.450M
YoY Change	46.54%
Accrued Expenses	$10.21M	$7.469M
YoY Change	42.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.83M	$9.919M
YoY Change	43.52%
LONG-TERM LIABILITIES
Long-Term Debt	$39.16M	$39.09M
YoY Change	0.67%
Other Long-Term Liabilities	$363.0K	$363.0K
YoY Change	9.34%
Total Long-Term Liabilities	$39.52M	$39.46M
YoY Change	0.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.83M	$9.919M
Total Long-Term Liabilities	$39.52M	$39.46M
Total Liabilities	$52.36M	$49.38M
YoY Change	6.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$186.5M	-$175.2M
YoY Change	22.77%
Common Stock	$3.000K	$3.000K
YoY Change	200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$68.96M	$77.75M	-$135.7M
YoY Change
Total Liabilities & Shareholders Equity	$121.3M	$127.1M
YoY Change	327.24%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$11.31M	-$8.654M	-$3.147M
YoY Change	135.93%	174.99%	-46.3%
Depreciation, Depletion And Amortization	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	-31.03%
Cash From Operating Activities	-$7.120M	-$8.390M	-$1.260M
YoY Change	181.42%	565.87%	-74.02%
INVESTING ACTIVITIES
Capital Expenditures	-$750.0K	-$480.0K	-$500.0K
YoY Change	1150.0%	-4.0%	117.39%
Acquisitions
YoY Change
Other Investing Activities	$8.480M	$6.220M	$0.00
YoY Change
Cash From Investing Activities	$7.730M	$5.740M	-$500.0K
YoY Change	-12983.33%	-1248.0%	117.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	580.0K	1.530M	190.0K
YoY Change	38.1%	705.26%	-161.29%
NET CHANGE
Cash From Operating Activities	-7.120M	-8.390M	-1.260M
Cash From Investing Activities	7.730M	5.740M	-500.0K
Cash From Financing Activities	580.0K	1.530M	190.0K
Net Change In Cash	1.190M	-1.120M	-1.570M
YoY Change	-154.84%	-28.66%	-70.87%
FREE CASH FLOW
Cash From Operating Activities	-$7.120M	-$8.390M	-$1.260M
Capital Expenditures	-$750.0K	-$480.0K	-$500.0K
Free Cash Flow	-$6.370M	-$7.910M	-$760.0K
YoY Change	157.89%	940.79%	-83.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24801172	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q1	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	20000	USD
CY2018Q2	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	8000	USD
CY2019Q1	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	66000	USD
CY2019Q2	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	56000	USD
CY2018Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2019Q2	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	86000	USD
CY2018Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2019Q2	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2018Q4	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	97093000	USD
CY2019Q2	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	91694000	USD
CY2019Q2	sibn	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2019Q2	sibn	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q2	sibn	Available For Sale Debt Securities Noncurrent Amortized Cost Basis AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis	5254000	USD
CY2018Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	300000	USD
CY2018Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	331000	USD
CY2019Q2	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	200000	USD
CY2019Q2	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	210000	USD
CY2018Q4	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2019Q2	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	94000	USD
CY2018Q4	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2019Q2	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2018Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	119951000	USD
CY2019Q2	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	103242000	USD
CY2018Q4	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	119961000	USD
CY2019Q2	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	103336000	USD
CY2018Q4	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	74019	shares
CY2019Q2	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	46811	shares
CY2019Q2	sibn	Stock Issued During Period Amount Restricted Stock Units StockIssuedDuringPeriodAmountRestrictedStockUnits	0	USD
CY2018Q2	sibn	Stock Issued During Period Value Issuance Of Common Stock Upon Exercise Of Unvested Stock Options StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfUnvestedStockOptions	0	USD
	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	28000	USD
	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	122000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2146000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2450000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8486000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9404000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	940000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6860000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7469000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	583000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	421000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3364000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3507000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	439000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	516000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	246927000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	252404000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	391000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	363000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1871000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1814000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	160000	USD
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1200000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	363000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	754000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1814000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3685000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22408000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	263000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	288000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	130000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	130000	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15316586	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15316586	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3838635	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3838635	shares
CY2018Q4	us-gaap	Assets Assets	138521000	USD
CY2019Q2	us-gaap	Assets Assets	127122000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	136042000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	119018000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	97103000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	91780000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	5262000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	97000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25120000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11496000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16233000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25120000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11496000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6175000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13624000	USD
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22858000	USD
CY2019Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6294000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24450757	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24761157	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24450757	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24761157	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3093000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7315000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8583000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17922000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1182000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2230000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1588000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3114000	USD
CY2019Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000	USD
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	907000	USD
CY2018Q2	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	400000	USD
CY2019Q2	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	356000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	395000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.04
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5425000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4987000	USD
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7400000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	224000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-48000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-98000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2564000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4972000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4194000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8960000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	12481000	USD
	us-gaap	Gross Profit GrossProfit	24145000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	14729000	USD
	us-gaap	Gross Profit GrossProfit	28194000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-462000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	338000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-194000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	916000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	514000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	725000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	320000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1092000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-237000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-102000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	1269000	USD
	us-gaap	Interest Expense InterestExpense	2544000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	1233000	USD
	us-gaap	Interest Expense InterestExpense	2463000	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2019Q2	us-gaap	Interest Payable Current InterestPayableCurrent	1163000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3343000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	4436000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	130000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	695000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1439000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	48329000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	49375000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138521000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127122000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9006000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9919000	USD
CY2019Q2	us-gaap	Long Term Debt LongTermDebt	39093000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	17778000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	17778000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4444000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	38963000	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39093000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	208000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1663000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-715000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	191000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5673000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15474000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-4201000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-3147000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7348000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9345000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-8654000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17999000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	14178000	USD
	us-gaap	Operating Expenses OperatingExpenses	28759000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	22867000	USD
	us-gaap	Operating Expenses OperatingExpenses	45131000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1697000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4614000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8138000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16937000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5408000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	833000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	855000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	934000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1052000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1184000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	550000	USD
CY2018Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
CY2019Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	133000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	339000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	325000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	310000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	25000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	59000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	84000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-21000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	54000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	33000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-19000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	12000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-7000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	360000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	363000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-249000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-320000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	167000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	82516000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	715000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	893000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1990000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1902000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	83600000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	208000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	567000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1263000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5518000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6039000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2154000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2532000	USD
CY2018Q4	us-gaap	Purchase Obligation PurchaseObligation	200000	USD
CY2019Q2	us-gaap	Purchase Obligation PurchaseObligation	300000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1296000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2502000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1946000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3629000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157177000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175176000	USD
CY2018Q2	us-gaap	Revenues Revenues	13663000	USD
	us-gaap	Revenues Revenues	26375000	USD
CY2019Q2	us-gaap	Revenues Revenues	16317000	USD
	us-gaap	Revenues Revenues	31308000	USD
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	388000	USD
CY2019Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	349000	USD
CY2018Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10318000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21285000	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16727000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	32542000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	754000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3685000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	27320	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	20.97
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	62964	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	630639	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.09
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.79
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2641198	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3024743	shares
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	190000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	125000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	442000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.27
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.76
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.10
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.61
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.91
CY2018Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	12066654	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	184130	shares
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1263000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-129378000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-133171000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-135703000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	90192000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	82755000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	77747000	USD
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0556
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	118548000	USD
CY2018Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	118548000	USD
CY2018Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	118548000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2019Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2019Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11871578	shares
CY2018Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11871578	shares
CY2018Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11871578	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3608283	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3603308	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24577938	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24484608	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company’s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s revenue and accounts receivable are spread across a large number of customers, primarily in the United States, and no one customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company and Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its iFuse Implant System, or iFuse, in 2009 in the United States, in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company's board of directors and stockholders approved a 1-for-18 reverse stock split of the Company's common stock and redeemable convertible preferred stock, which was effected on October 4, 2018. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse split. All issued and outstanding share and per share amounts of common stock, redeemable convertible preferred stock, stock options, and warrants included in the accompanying consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 16, 2018, the Company’s Registration Statement on Form S-1 (File No. 333-227445) relating to the initial public offering (IPO) of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, the Company sold </font><font style="font-family:inherit;font-size:10pt;">8,280,000</font><font style="font-family:inherit;font-size:10pt;"> shares at an initial public offering price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$113.4 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company, net of underwriting discounts and commissions and offering costs. Upon the closing of the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,066,654</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and the Company's outstanding warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">156,550</font><font style="font-family:inherit;font-size:10pt;"> shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">160,657</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in additional paid-in-capital.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001459839-19-000035-index-headers.html	Edgar Link	pending
0001459839-19-000035-index.html	Edgar Link	pending
0001459839-19-000035.txt	Edgar Link	pending
0001459839-19-000035-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sibn-20190630.xml	Edgar Link	completed
sibn-20190630.xsd	Edgar Link	pending
sibn-20190630_cal.xml	Edgar Link	unprocessable
sibn-20190630_def.xml	Edgar Link	unprocessable
sibn-20190630_lab.xml	Edgar Link	unprocessable
sibn-20190630_pre.xml	Edgar Link	unprocessable
sibn-ex311_630201910xq.htm	Edgar Link	pending
sibn-ex312_630201910xq.htm	Edgar Link	pending
sibn-ex321_630201910xq.htm	Edgar Link	pending
sibn630201910-q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2019 Q3 Form 10-Q Financial Statement

#000145983919000035 Filed on August 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2019 Q3 Form 10-Q Financial Statement

#000145983919000035 Filed on August 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn